Afatinib* is being studied in a comprehensive lung cancer clinical trial programme.
*In the EU, Taiwan and Mexico, afatinib is approved under the brand name GIOTRIF^®, and in the U.S. under the brand name GILOTRIFTM for use in patients with distinct types of NSCLC. Afatinib is under regulatory review by health authorities in Asia and other countries.